Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Trade names | Spikevax[1] |
Routes of administration | Intramuscular |
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]
Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers.[4] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[5]
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[6] As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.[7] Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.[8]
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Development |
| ||||||||||
Classes |
| ||||||||||
Administration |
| ||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers |
| ||||||||||
Controversy |
| ||||||||||
Related |
| ||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccinesorvaccination is a stub. You can help Wikipedia by expanding it. |